Vertex Pharmaceuticals Inc (VRTX) Stock Analysis

Vertex Pharmaceuticals Inc (VRTX) is a publicly traded company in the HEALTHCARE sector. It trades at $425.09, carries a market capitalization of $111.27B, a price-to-earnings ratio of 26.05. This page summarizes the public market data, fundamentals, and frequently asked questions for VRTX, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Vertex Pharmaceuticals Inc currently has a Bullish sentiment score of 0.22.

About Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Inc. is a premier biopharmaceutical company based in Boston, Massachusetts, recognized for its pioneering development and commercialization of breakthrough therapies for serious diseases, most notably cystic fibrosis (CF). With an impressive array of approved therapies powered by its proprietary scientific innovations, Vertex has significantly changed the treatment paradigm for CF patients and remains steadfast in addressing critical unmet medical needs. The company is ...

GNG Research Analysis

GNG Research scores Vertex Pharmaceuticals Inc (VRTX) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for VRTX.

Frequently Asked Questions

Does VRTX pay dividends?

Vertex Pharmaceuticals Inc (VRTX) does not currently pay a regular dividend.

What is VRTX's P/E ratio?

Vertex Pharmaceuticals Inc has a price-to-earnings (P/E) ratio of 26.05.

What is VRTX's market cap?

Vertex Pharmaceuticals Inc (VRTX) has a market capitalization of $111.27B with a current stock price of $425.09.